IDEAYA Biosciences, Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- IDEAYA Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $1.10M, a 169.51% increase year-over-year.
- IDEAYA Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $1.20M, a 5.38% increase year-over-year.
- IDEAYA Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-12-31 was $1.55M, a 22.26% decline year-over-year.
- IDEAYA Biosciences, Inc. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $473.00K, a 80.17% decline year-over-year.
- IDEAYA Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2025 was $3.56M, a 71.46% decline from fiscal 2024.
- IDEAYA Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2024 was $12.48M, a 30.59% increase from fiscal 2023.
- IDEAYA Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2023 was $9.56M, a 560.15% increase from fiscal 2022.
- IDEAYA Biosciences, Inc. stock issued during period, value, stock options exercised for fiscal 2022 was $1.45M, a 4.11% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $1.10M 10-Q · filed 2026-08-04 | $4.32M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $1.20M 10-Q · filed 2026-05-05 | $3.63M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $3.56M 10-K · filed 2026-02-17 |
| 2025-09-30 | $473.00K 10-Q · filed 2025-11-04 | $4.01M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $410.00K 10-Q · filed 2026-08-04 | $5.92M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $1.13M 10-Q · filed 2026-05-05 | $8.16M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $1.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $12.48M 10-K · filed 2026-02-17 |
| 2024-09-30 | $2.38M 10-Q · filed 2025-11-04 | $16.34M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | $2.65M 10-Q · filed 2025-08-05 | $15.81M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $5.46M 10-Q · filed 2025-05-06 | $14.65M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $5.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $9.56M 10-K · filed 2026-02-17 |
| 2023-09-30 | $1.86M 10-Q · filed 2024-11-04 | $4.23M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-06-30 | $1.49M 10-Q · filed 2024-08-06 | $2.52M derived: sum of 4 quarters · filed 2025-02-18 |
| 2023-03-31 | $366.00K 10-Q · filed 2024-05-07 | $1.15M derived: sum of 4 quarters · filed 2025-02-18 |
| 2022-12-31 | $517.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | $1.45M 10-K · filed 2025-02-18 |
| 2022-09-30 | $148.00K 10-Q · filed 2023-11-07 | $1.28M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-06-30 | $122.00K 10-Q · filed 2023-08-10 | $1.94M derived: sum of 4 quarters · filed 2024-02-20 |
| 2022-03-31 | $662.00K 10-Q · filed 2023-05-09 | $2.06M derived: sum of 4 quarters · filed 2024-02-20 |
| 2021-12-31 | $347.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $1.51M 10-K · filed 2024-02-20 |
| 2021-09-30 | $806.00K 10-Q · filed 2022-11-08 | $1.33M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $243.00K 10-Q · filed 2022-08-15 | $826.00K derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $112.00K 10-Q · filed 2022-05-10 | $1.28M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | $174.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $1.20M 10-K · filed 2023-03-07 |
| 2020-09-30 | $297.00K 10-Q · filed 2021-11-15 | $1.07M derived: sum of 4 quarters · filed 2022-03-18 |
| 2020-06-30 | $694.00K 10-Q · filed 2021-08-10 | $967.00K derived: sum of 4 quarters · filed 2022-03-18 |
| 2020-03-31 | $37.00K 10-Q · filed 2021-05-10 | $343.00K derived: sum of 4 quarters · filed 2022-03-18 |
| 2019-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $307.00K 10-K · filed 2022-03-18 |
| 2019-09-30 | $190.00K 10-Q · filed 2020-11-12 | $264.00K derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-06-30 | $70.00K 10-Q · filed 2020-08-12 | $97.00K derived: sum of 4 quarters · filed 2021-03-23 |
| 2019-03-31 | $1.00K 10-Q · filed 2020-05-12 | |
| 2018-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | $28.00K 10-K · filed 2021-03-23 |
| 2018-09-30 | $23.00K 10-Q · filed 2019-11-13 | |
| 2017-12-31 | $0.00 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |